Glaucoma as a neurodegenerative disease

Current Opinion in Ophthalmology

Volumn 18, Issue 2, 2007, Pages 110-114

  Gupta, Neeru ^a   Yücel, Yeni H ^a,b  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Alzheimer's disease; Lateral geniculate nucleus; Optic nerve; Parkinson's disease; Retinal ganglion cells; Visual cortex

Indexed keywords

GLUTAMIC ACID;

BRAIN; DEGENERATIVE DISEASE; GENICULATE BODY; GLAUCOMA; HUMAN; INTRAOCULAR PRESSURE; MEDICAL LITERATURE; NERVE CELL DEGENERATION; NERVE CELL LESION; NERVE CELL NECROSIS; PRIORITY JOURNAL; RETINA GANGLION CELL; REVIEW; RISK FACTOR; SYNAPSE; VISUAL CORTEX; VISUAL SYSTEM;

ANIMALS; APOPTOSIS; DISEASE PROGRESSION; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; OPTIC DISK; OPTIC NERVE DISEASES; PROGNOSIS; RETINAL GANGLION CELLS;

EID: 33847034391     PISSN: 10408738     EISSN: None     Source Type: Journal    
DOI: 10.1097/ICU.0b013e3280895aea     Document Type: Review

References (60)

1. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2006; 90:262-267. An excellent review of published data and prevalence models to estimate the number of people with open and closed angle glaucoma worldwide in 2010 and 2020.
2. Weinreb RN, Khaw PT. Primary open-angle glaucoma. Lancet 2004; 363:1711-1720.
3. Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002; 120:1268-1279.
4. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2000; 130:429-440.
5. Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol 1998; 126:487-497.
6. Araujo SV, Spaeth GL, Roth SM, et al. A ten-year follow-up on a prospective, randomized trial of postoperative corticosteroids after trabeculectomy. Ophthalmology 1995; 102:1753-1759.
7. Jay JL, Allan D. The benefit of early trabeculectomy versus conventional management in primary open angle glaucoma relative to severity of disease. Eye 1989; 3 (Pt 5):528-535.
8. Nouri-Mahdavi K, Brigatti L, Weitzman M, et al. Outcomes of trabeculectomy for primary open-angle glaucoma. Ophthalmology 1995; 102:1760-1769.
9. Quigley HA. Neuronal death in glaucoma. Prog Retin Eye Res 1999; 18:39-57.
10. Weber AJ, Harman CD. Structure-function relations of parasol cells in the normal and glaucomatous primate retina. Invest Ophthalmol Vis Sci 2005; 46:3197-3207.
11. Yucel YH, Zhang Q, Gupta N, et al. Loss of neurons in magnocellular and parvocellular layers of the lateral geniculate nucleus in glaucoma. Arch Ophthalmol 2000; 118:378-384.
12. Yucel YH, Zhang Q, Weinreb RN, et al. Atrophy of relay neurons in magno- and parvocellular layers in the lateral geniculate nucleus in experimental glaucoma. Invest Ophthalmol Vis Sci 2001; 42:3216-3222.
13. Yucel YH, Zhang Q, Weinreb RN, et al. Effects of retinal ganglion cell loss on magno-, parvo-, koniocellular pathways in the lateral geniculate nucleus and visual cortex in glaucoma. Prog Retin Eye Res 2003; 22:465-481.
14. Weber AJ, Chen H, Hubbard WC, et al. Experimental glaucoma and cell size, density, and number in the primate lateral geniculate nucleus. Invest Ophthalmol Vis Sci 2000; 41:1370-1379.
15. Gupta N, Ang LC, Noel de Tilly L, et al. Human glaucoma and neural degeneration in intracranial optic nerve, lateral geniculate nucleus, and visual cortex. Br J Ophthalmol 2006; 90:674-678. This paper provides postmortem human glaucoma evidence for neuropathology within the visual system correlating with visual field deficits.
16. Bredesen DE, Rao RV, Mehlen P. Cell death in the nervous system. Nature 2006; 443:796-802. This is an excellent paper examining cell death pathways and its mediators in neurodegenerative diseases.
17. Lang AE, Lozano AM. Parkinson's disease. First of two parts. N Engl J Med 1998; 339:1044-1053.
18. Lang AE, Lozano AM. Parkinson's disease. Second of two parts. N Engl J Med 1998; 339:1130-1143.
19. Harwerth RS, Carter-Dawson L, Smith EL 3rd, et al. Neural losses correlated with visual losses in clinical perimetry. Invest Ophthalmol Vis Sci 2004; 45:3152-3160.
20. Harwerth RS, Quigley HA. Visual field defects and retinal ganglion cell losses in patients with glaucoma. Arch Ophthalmol 2006; 124:853-859. This article correlates visual field findings with retinal ganglion cell density in postmortem eyes.
21. Su JH, Deng G, Cotman CW. Transneuronal degeneration in the spread of Alzheimer's disease pathology: immunohistochemical evidence for the transmission of tau hyperphosphorylation. Neurobiol Dis 1997; 4:365-375.
22. Kiernan JA, Hudson AJ. Changes in sizes of cortical and lower motor neurons in amyotrophic lateral sclerosis. Brain 1991; 114 (Pt 2):843-853.
23. Gupta N, Yucel YH. Glaucoma and the brain. J Glaucoma 2001; 10:S28-S29.
24. Radius RL, Pederson JE. Laser-induced primate glaucoma. II. Histopathology. Arch Ophthalmol 1984; 102:1693-1698.
25. Vickers JC, Hof PR, Schumer RA, et al. Magnocellular and parvocellular visual pathways are both affected in a macaque monkey model of glaucoma. Aust N Z J Ophthalmol 1997; 25:239-243.
26. Crawford ML, Harwerth RS, Smith EL 3rd, et al. Glaucoma in primates: cytochrome oxidase reactivity in parvo- and magnocellular pathways. Invest Ophthalmol Vis Sci 2000; 41:1791-1802.
27. Lam DY, Kaufman PL, Gabelt BT, et al. Neurochemical correlates of cortical plasticity after unilateral elevated intraocular pressure in a primate model of glaucoma. Invest Ophthalmol Vis Sci 2003; 44:2573-2581.
28. Crawford ML, Harwerth RS, Smith EL 3rd, et al. Experimental glaucoma in primates: changes in cytochrome oxidase blobs in V1 cortex. Invest Ophthalmol Vis Sci 2001; 42:358-364.
29. Gupta N, Ly T, Zhang Q, et al. Chronic ocular hypertension induces dendrite pathology in the lateral geniculate nucleus of the brain. Exp Eye Res 2007; 84:176-184. Early injury to the dendrites of neurons in the lateral geniculate nucleus occurs following elevated IOP without significant RGC axon loss.
30. Chaturvedi N, Hedley-Whyte ET, Dreyer EB. Lateral geniculate nucleus in glaucoma. Am J Ophthalmol 1993; 116:182-188.
31. Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006; 443:787-795.
32. Tezel G. Oxidative stress in glaucomatous neurodegeneration: mechanisms and consequences. Prog Retin Eye Res 2006; 25:490-513. A detailed examination of oxidative stress in relation to glial cell pathology and immune response is provided.
33. Lipton SA. The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism. Curr Alzheimer Res 2005; 2:155-165.
34. Lansbury PT, Lashuel HA. A century-old debate on protein aggregation and neurodegeneration enters the clinic. Nature 2006; 443:774-779. An excellent review of abnormal protein aggregation and its clinical relevance in neurodegenerative diseases.
35. Castegna A, Thongboonkerd V, Klein JB, et al. Proteomic identification of nitrated proteins in Alzheimer's disease brain. J Neurochem 2003; 85:1394-1401.
36. Giasson BI, Duda JE, Murray IV, et al. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 2000; 290:985-989.
37. Beckman JS, Carson M, Smith CD, et al. ALS, SOD and peroxynitrite. Nature 1993; 364:584.
38. Abe K, Pan LH, Watanabe M, et al. Induction of nitrotyrosine-like immunoreactivity in the lower motor neuron of amyotrophic lateral sclerosis. Neurosci Lett 1995; 199:152-154.
39. Neufeld AH. Nitric oxide: a potential mediator of retinal ganglion cell damage in glaucoma. Surv Ophthalmol 1999; 43 (Suppl 1):S129-S135.
40. Luthra A, Gupta N, Kaufman PL, et al. Oxidative injury by peroxynitrite in neural and vascular tissue of the lateral geniculate nucleus in experimental glaucoma. Exp Eye Res 2005; 80:43-49.
41. Riederer P, Hoyer S. From benefit to damage. Glutamate and advanced glycation end products in Alzheimer brain. J Neural Transm 2006; 113:1671-1677.
42. Zhang L, Dawson VL, Dawson TM. Role of nitric oxide in Parkinson's disease. Pharmacol Ther 2006; 109:33-41.
43. Beal MF. Excitotoxicity and nitric oxide in Parkinson's disease pathogenesis. Ann Neurol 1998; 44:S110-S114.
44. Van Den Bosch L, Van Damme P, Bogaert E, et al. The role of excitotoxicity in the pathogenesis of amyotrophic lateral sclerosis. Biochim Biophys Acta 2006; 1762:1068-1082.
45. Dreyer EB, Zurakowski D, Schumer RA, et al. Elevated glutamate levels in the vitreous body of humans and monkeys with glaucoma. Arch Ophthalmol 1996; 114:299-305.
46. Wamsley S, Gabelt BT, Dahl DB, et al. Vitreous glutamate concentration and axon loss in monkeys with experimental glaucoma. Arch Ophthalmol 2005; 123:64-70.
47. Hare WA, WoldeMussie E, Weinreb RN, et al. Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey. II: Structural measures. Invest Ophthalmol Vis Sci 2004; 45:2640-2651.
48. Yucel YH, Gupta N, Zhang Q, et al. Memantine protects neurons from shrinkage in the lateral geniculate nucleus in experimental glaucoma. Arch Ophthalmol 2006; 124:217-225. Memantine attenuates neuron shrinkage in experimental primate glaucoma and this suggests a role for excitotoxicity in transsynaptic neural degeneration.
49. Shohami E, Ginis I, Hallenbeck JM. Dual role of tumor necrosis factor alpha in brain injury. Cytokine Growth Factor Rev 1999; 10:119-130.
50. Yuan L, Neufeld AH. Tumor necrosis factor-alpha: a potentially neurodestructive cytokine produced by glia in the human glaucomatous optic nerve head. Glia 2000; 32:42-50.
51. Nakazawa T, Nakazawa C, Matsubara A, et al. Tumor necrosis factor-alpha mediates oligodendrocyte death and delayed retinal ganglion cell loss in a mouse model of glaucoma. J Neurosci 2006; 26:12633-12641. This paper offers interesting insights into tumor necrosis factor-alpha in a mouse model of glaucoma.
52. McKinnon SJ, Lehman DM, Kerrigan-Baumrind LA, et al. Caspase activation and amyloid precursor protein cleavage in rat ocular hypertension. Invest Ophthalmol Vis Sci 2002; 43:1077-1087.
53. Le A, Mukesh BN, McCarty CA, et al. Risk factors associated with the incidence of open-angle glaucoma: the visual impairment project. Invest Ophthalmol Vis Sci 2003; 44:3783-3789.
54. Vickers JC, Craig JE, Stankovich J, et al. The apolipoprotein epsilon4 gene is associated with elevated risk of normal tension glaucoma. Mol Vis 2002; 8:389-393.
55. Reisberg B, Doody R, Stoffler A, et al. A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease. Arch Neurol 2006; 63:49-54.
56. Gupta N, Krishnadev N, Hamstra SJ, et al. Depth perception deficits in glaucoma suspects. Br J Ophthalmol 2006; 90:979-981. Abnormalities in depth perception in glaucoma and glaucoma suspects are detected and interpreted in the context of possible visual cortex and afferent visual system pathway changes.
57. Fujita N, Tanaka H, Takanashi M, et al. Lateral geniculate nucleus: anatomic and functional identification by use of MR imaging. AJNR Am J Neuroradiol 2001; 22:1719-1726.
58. Duncan RO, Sample PA, Weinreb RN, et al. Retinotopic organization of primary visual cortex in glaucoma: Comparing fMRI measurements of cortical function with visual field loss. Prog Retin Eye Res 2007; 26:38-56. An outstanding paper using fMRI demonstrates an altered BOLD signal in human V1 in POAG patients consistent with visual field loss.
59. Yoneda S, Hara H, Hirata A, et al. Vitreous fluid levels of beta-amyloid(1-42) and tau in patients with retinal diseases. Jpn J Ophthalmol 2005; 49:106-108.
60. Grus FH, Joachim SC, Bruns K, et al. Serum autoantibodies to alpha-fodrin are present in glaucoma patients from Germany and the United States. Invest Ophthalmol Vis Sci 2006; 47:968-976. This paper demonstrates that autoantibodies to a degraded protein may represent a potential biomarker for disease in glaucoma patients.